Larry Gold, SomaLogic
SomaLogic has built a proteomics platform in which small sample volumes – under 10 mliters – are used to measure more than a thousand proteins with the accuracy and sensitivity of individual ELISAs. Because the throughput of the platform is high, unbiased biomarker discovery can be accomplished quickly. Gratifyingly, with the present content of about a thousand proteins, many disease conditions yield tens of biomarkers in the first clinical experiment. Content expansion is underway.
Sample matrices include serum, plasma, whole blood, CSF, tissue extracts, and more. In some clinical experiments we have compared blood changes in protein concentrations with biopsy protein concentrations. It is clear that some proteins overproduced in a pathologic tissue make themselves seen as elevated protein levels in blood.
Thousands of samples have been run through the platform and an early picture of the differences and similarities in various disease states is emerging.